Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Dr Leal on the Development of DLL3-Targeted Agents in SCLC

February 3rd 2024, 6:20pm

PER® Winter Lung Cancer Conference

Ticiana Leal, MD, discusses the variety of DLL3-targeted agents in development for patients with small cell lung cancer and neuroendocrine tumors.

Dr Pellini on the Development of Increasingly Sensitive ctDNA Assays in NSCLC

February 3rd 2024, 12:55am

PER® Winter Lung Cancer Conference

Bruna Pellini, MD, discusses the importance of developing circulating tumor DNA assays with increased sensitivity.

Dr Rodriguez on the Use of HER2-Directed Therapies in NSCLC

February 3rd 2024, 12:45am

PER® Winter Lung Cancer Conference

Estelamari Rodriguez, MD, MPH, discusses adverse effects associated with HER2-directed antibody-drug conjugates in non–small cell lung cancer.

Dr Salani on the De-Escalation of Therapy in Gynecologic Oncology

January 29th 2024, 9:51pm

SGO Winter Meeting

Ritu Salani, MD, discusses the de-escalation of therapy and unmet needs within the landscape of gynecologic oncology.

Morphologic Type and Tumor Stage May Inform Real-World Outcomes in RCC

January 28th 2024, 11:00am

Genitourinary Cancers Symposium (ASCO GU)

Real-world recurrence and prognosis was determined through the identification of morphologic RCC types and tumor stages.

Subcutaneous Nivolumab Provides Clinical Equipoise to Standard IV Dosing in ccRCC

January 27th 2024, 9:21pm

Genitourinary Cancers Symposium (ASCO GU)

Subcutaneous nivolumab coformulated with rHuPH20 demonstrated noninferiority of PK exposures vs intravenous nivolumab in metastatic ccRCC.

Dr George on the Efficacy and Safety of Subcutaneous Nivolumab in ccRCC

January 27th 2024, 9:15pm

Genitourinary Cancers Symposium (ASCO GU)

Saby George, MD, FACP, discusses the efficacy and safety of subcutaneous nivolumab in patients with clear cell renal cell carcinoma, according to findings from the phase 3 CheckMate 67T study.

Adjuvant Nivolumab Does Not Provide DFS Advantage in Localized, High-Risk RCC

January 27th 2024, 9:10pm

Genitourinary Cancers Symposium (ASCO GU)

Adjuvant nivolumab monotherapy did not yield a disease-free survival benefit vs placebo in patients with localized renal cell carcinoma.

Adjuvant Pembrolizumab Significantly Prolongs OS vs Placebo in ccRCC

January 27th 2024, 8:57pm

Genitourinary Cancers Symposium (ASCO GU)

Treatment with adjuvant pembrolizumab significantly improved overall survival vs placebo in patients with clear cell renal cell carcinoma.

Extended Follow-Up Confirm Efficacy of First-Line Pembrolizumab/Lenvatinib Combo in Advanced Non–Clear Cell RCC

January 27th 2024, 7:41pm

Genitourinary Cancers Symposium (ASCO GU)

Frontline pembrolizumab plus lenvatinib continues to show benefit vs historical controls in advanced non–clear cell renal cell carcinoma.

Network Meta-Analysis Sheds Light on Efficacy of Lenvatinib Plus Pembrolizumab Vs SOC in Advanced RCC

January 27th 2024, 7:30pm

Genitourinary Cancers Symposium (ASCO GU)

Lenvatinib/pembrolizumab shows a trend of improved PFS and overall response rate vs standard immunotherapies in advanced renal cell carcinoma.

Belzutifan Improves Symptoms and Extends Time to Treatment Deterioration in Advanced RCC

January 27th 2024, 6:25pm

Genitourinary Cancers Symposium (ASCO GU)

Belzutifan treatment led to improved quality of life outcomes vs treatment with everolimus in patients with advanced renal cell carcinoma.

Adjuvant Pembrolizumab Improves DFS, But Not OS, in Locally Advanced/Muscle-Invasive Urothelial Carcinoma

January 27th 2024, 5:30pm

Genitourinary Cancers Symposium (ASCO GU)

Adjuvant pembrolizumab generated a disease-free survival benefit vs observation in patients with muscle-invasive and locally advanced urothelial carcinoma.

Enfortumab Vedotin Plus Pembrolizumab Maintains Survival Advantage Across Advanced Urothelial Cancer Subgroups

January 27th 2024, 5:13pm

Genitourinary Cancers Symposium (ASCO GU)

Enfortumab vedotin plus pembrolizumab showed consistent overall survival and progression-free survival benefit in all patients enrolled in EV-302.

Onvansertib Induces Preclinical Anti-Tumorigenic Effects in Endometrioid Endometrial Cancer

January 27th 2024, 4:40pm

SGO Winter Meeting

Nikita Sinha, MD, discusses the effects of onvansertib on cellular proliferation, adhesion, apoptosis, and stress in endometrial cancer cells.

Frontline Pembrolizumab Plus Cabozantinib Elicits Responses in Cisplatin-Ineligible Urothelial Carcinoma

January 27th 2024, 4:20pm

Genitourinary Cancers Symposium (ASCO GU)

Pembrolizumab plus cabozantinib was efficacious in the first-line treatment of patients with cisplatin-ineligible urothelial carcinoma.

Dr Apolo on Adjuvant Pembrolizumab in Muscle-Invasive Urothelial Carcinoma

January 27th 2024, 2:25am

Genitourinary Cancers Symposium (ASCO GU)

Andrea B. Apolo, MD, discusses the AMBASSADOR Alliance A031501 trial of adjuvant pembrolizumab in locally advanced/muscle-invasive urothelial carcinoma.

SGO Winter Meeting Spotlights Key Developments and Debates Across Gynecologic Oncology

January 26th 2024, 10:50pm

SGO Winter Meeting

Ritu Salani, MD, provides an overview of the variety of sessions presented at the 2024 SGO Winter Meeting.

Urinary MRD Status Potentially Predictive of Recurrence in BCG-Unresponsive NMIBC

January 26th 2024, 10:11pm

Genitourinary Cancers Symposium (ASCO GU)

Assessment of urinary MRD status identified and enabled quantification of molecular responses with nadofaragene firadenovec in BCG-unresponsive NMIBC.

Dr Nizam on Enfortumab Vedotin After Maintenance Avelumab in Urothelial Cancer

January 26th 2024, 9:40pm

Genitourinary Cancers Symposium (ASCO GU)

Amanda Nizam, MD, discusses findings from the UNITE study of enfortumab vedotin after maintenance avelumab in patients with advanced urothelial carcinoma.